Paclitaxel Ebewe 6 mg/ml koncentrat za raztopino za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

paclitaxel ebewe 6 mg/ml koncentrat za raztopino za infundiranje

ebewe pharma - paklitaksel - koncentrat za raztopino za infundiranje - paklitaksel 6 mg / 1 ml - paklitaksel

Paxene Evropska unija - slovenščina - EMA (European Medicines Agency)

paxene

norton healthcare ltd. - paklitaksel - sarcoma, kaposi; carcinoma, non-small-cell lung; ovarian neoplasms; breast neoplasms - antineoplastična sredstva - paxene je indiciran za zdravljenje bolnikov z:• napredno za aidsom kaposi ' s sarkom (aids-cs), ki je ni pred liposomal anthracycline terapije;• metastatskim karcinom dojk (mbc), ki je ni, ali pa niso kandidati za standardne anthracycline-ki vsebujejo terapije;• napredno karcinom iz jajčnikov (aoc) ali z preostale bolezni (> 1 cm) po začetnem laparotomija, v kombinaciji z cisplatin kot prvo linijo zdravljenja;• metastatskim karcinom iz jajčnikov (moc) po izpadu platinum, ki vsebujejo kombinacijo terapija brez taxanes kot drugi liniji zdravljenja;• non-small cell karcinom pljuč (nsclc), ki niso kandidati za potencialno kurativno operacijo in/ali obsevanjem, v kombinaciji z cisplatin. omejeni podatki o učinkovitosti podpirajo to indikacijo (glejte poglavje 5).

Paclitaxin 6 mg/ml koncentrat za raztopino za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

paclitaxin 6 mg/ml koncentrat za raztopino za infundiranje

pharmachemie b.v. - paklitaksel - koncentrat za raztopino za infundiranje - paklitaksel 6 mg / 1 ml - paklitaksel

Paclitaxin 6 mg/ml koncentrat za raztopino za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

paclitaxin 6 mg/ml koncentrat za raztopino za infundiranje

pharmachemie b.v. - paklitaksel - koncentrat za raztopino za infundiranje - paklitaksel 6 mg / 1 ml - paklitaksel

Paclitaxin 6 mg/ml koncentrat za raztopino za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

paclitaxin 6 mg/ml koncentrat za raztopino za infundiranje

pharmachemie b.v. - paklitaksel - koncentrat za raztopino za infundiranje - paklitaksel 6 mg / 1 ml - paklitaksel

Paclitaxin 6 mg/ml koncentrat za raztopino za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

paclitaxin 6 mg/ml koncentrat za raztopino za infundiranje

pharmachemie b.v. - paklitaksel - koncentrat za raztopino za infundiranje - paklitaksel 6 mg / 1 ml - paklitaksel

Tecentriq Evropska unija - slovenščina - EMA (European Medicines Agency)

tecentriq

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastična sredstva - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq kot monotherapy je indiciran za zdravljenje odraslih bolnikov z lokalno napredno ali metastatskim nsclc po predhodno kemoterapijo. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq kot monotherapy je indiciran za zdravljenje odraslih bolnikov z lokalno napredno ali metastatskim nsclc po predhodno kemoterapijo. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Paklitaksel Kabi 6 mg/ml koncentrat za raztopino za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

paklitaksel kabi 6 mg/ml koncentrat za raztopino za infundiranje

fresenius kabi deutschland gmbh - paklitaksel - koncentrat za raztopino za infundiranje - paklitaksel 6 mg / 1 ml - paklitaksel

Paklitaksel Kabi 6 mg/ml koncentrat za raztopino za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

paklitaksel kabi 6 mg/ml koncentrat za raztopino za infundiranje

fresenius kabi deutschland gmbh - paklitaksel - koncentrat za raztopino za infundiranje - paklitaksel 6 mg / 1 ml - paklitaksel

Paklitaksel Kabi 6 mg/ml koncentrat za raztopino za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

paklitaksel kabi 6 mg/ml koncentrat za raztopino za infundiranje

fresenius kabi deutschland gmbh - paklitaksel - koncentrat za raztopino za infundiranje - paklitaksel 6 mg / 1 ml - paklitaksel